(Q40164172)

English

Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, Phase 3 NAVIGATE trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, Phase 3 NAVIGATE trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

phase III clinical trial

0 references

9

object named as

L Puig

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

author name string

R G Langley

1

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

T-F Tsai

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

S Flavin

3

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

M Song

4

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

B Randazzo

5

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Y Wasfi

6

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

J Jiang

7

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

S Li

8

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

language of work or name

0 references

publication date

21 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

British Journal of Dermatology

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Global epidemiology of psoriasis: a systematic review of incidence and prevalence

1 reference

https://api.crossref.org/works/10.1111%2FBJD.15750

21 January 2018

Pathogenesis and therapy of psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FBJD.15750

21 January 2018

Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.15750

21 January 2018

Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FBJD.15750

21 January 2018

IL-23 promotes maintenance but not commitment to the Th17 lineage

1 reference

https://api.crossref.org/works/10.1111%2FBJD.15750

21 January 2018

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://api.crossref.org/works/10.1111%2FBJD.15750

21 January 2018

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

1 reference

https://api.crossref.org/works/10.1111%2FBJD.15750

21 January 2018

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active compa

1 reference

https://api.crossref.org/works/10.1111%2FBJD.15750

21 January 2018

Secukinumab in plaque psoriasis--results of two phase 3 trials

1 reference

https://api.crossref.org/works/10.1111%2FBJD.15750

21 January 2018

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FBJD.15750

21 January 2018

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-bl

1 reference

https://api.crossref.org/works/10.1111%2FBJD.15750

21 January 2018

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FBJD.15750

21 January 2018

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.15750

21 January 2018

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FBJD.15750

21 January 2018

The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.15750

21 January 2018

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.15750

21 January 2018

Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary

1 reference

https://api.crossref.org/works/10.1111%2FBJD.15750

21 January 2018

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.15750

21 January 2018

Patient-relevant treatment goals in psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FBJD.15750

21 January 2018

Clinical meaningfulness of complete skin clearance in psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.15750

21 January 2018

Identifiers

10.1111/BJD.15750

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40164172&oldid=1887814324"